Teva Pharmaceutical Industries LTD TEVA
We take great care to ensure that the data presented and summarized in this overview for TEVA PHARMACEUTICAL INDUSTRIES LTD is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TEVA
View all-
Black Rock Inc. New York, NY43MShares$778 Million0.02% of portfolio
-
Ion Asset Management Ltd. George Town, Grand Cayman, E936.3MShares$657 Million41.14% of portfolio
-
Clal Insurance Enterprises Holdings LTD Tel Aviv, L332.3MShares$585 Million5.5% of portfolio
-
Migdal Insurance & Financial Holdings Ltd.29.1MShares$527 Million7.9% of portfolio
-
Menora Mivtachim Holdings Ltd.28.8MShares$522 Million3.23% of portfolio
-
Exor Capital LLP London, X026.5MShares$479 Million15.49% of portfolio
-
Phoenix Holdings Ltd. Givatayim, L325.4MShares$460 Million6.61% of portfolio
-
Slate Path Capital LP New York, NY20.2MShares$365 Million6.44% of portfolio
-
State Street Corp Boston, MA17.7MShares$321 Million0.01% of portfolio
-
Rubric Capital Management LP New York, NY17.3MShares$312 Million8.31% of portfolio
Latest Institutional Activity in TEVA
Top Purchases
Top Sells
About TEVA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
Insider Transactions at TEVA
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 02
2024
|
Varda Shalev |
BUY
Exercise of conversion of derivative security
|
Direct |
12,872
+50.0%
|
-
|
Aug 12
2024
|
Richard Daniell Exec. VP, European Commercial |
SELL
Open market or private sale
|
Direct |
98,943
-100.0%
|
$1,682,031
$17.3 P/Share
|
Aug 09
2024
|
Angus Grant EVP, Business Development |
SELL
Open market or private sale
|
Direct |
4,065
-31.48%
|
$69,105
$17.28 P/Share
|
Aug 09
2024
|
Angus Grant EVP, Business Development |
BUY
Exercise of conversion of derivative security
|
Direct |
12,913
+50.0%
|
-
|
Aug 09
2024
|
Eric A Hughes |
SELL
Open market or private sale
|
Direct |
45,060
-100.0%
|
$766,020
$17.38 P/Share
|
Aug 01
2024
|
Eric A Hughes |
SELL
Open market or private sale
|
Direct |
24,537
-35.26%
|
$417,129
$17.25 P/Share
|
Aug 01
2024
|
Eric A Hughes |
BUY
Exercise of conversion of derivative security
|
Direct |
52,742
+43.11%
|
-
|
Jun 18
2024
|
Roberto Mignone |
SELL
Open market or private sale
|
Indirect |
519,000
-34.6%
|
$8,823,000
$17.03 P/Share
|
Jun 15
2024
|
Roberto Mignone |
BUY
Exercise of conversion of derivative security
|
Direct |
21,108
+1.31%
|
-
|
Jun 15
2024
|
Tal Zvi Zaks |
BUY
Exercise of conversion of derivative security
|
Direct |
21,108
+30.05%
|
-
|
Jun 15
2024
|
Rosemary A Crane |
BUY
Exercise of conversion of derivative security
|
Direct |
21,108
+16.92%
|
-
|
Jun 15
2024
|
Ronit Satchi Fainaro |
BUY
Exercise of conversion of derivative security
|
Direct |
21,108
+19.3%
|
-
|
Jun 15
2024
|
Perry Nisen |
BUY
Exercise of conversion of derivative security
|
Direct |
21,108
+18.07%
|
-
|
Jun 15
2024
|
Gerald M Lieberman |
BUY
Exercise of conversion of derivative security
|
Direct |
21,108
+16.6%
|
-
|
Jun 15
2024
|
Janet S. Vergis |
BUY
Exercise of conversion of derivative security
|
Direct |
21,108
+24.78%
|
-
|
Jun 15
2024
|
Sol J Barer |
BUY
Exercise of conversion of derivative security
|
Direct |
37,598
+8.42%
|
-
|
Jun 15
2024
|
Amir Elstein |
BUY
Exercise of conversion of derivative security
|
Direct |
21,108
+1.0%
|
-
|
May 16
2024
|
Amir Weiss Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
12,635
-70.93%
|
$202,160
$16.65 P/Share
|
May 15
2024
|
Amir Weiss Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
15,500
-46.53%
|
$248,000
$16.8 P/Share
|
May 13
2024
|
Vikki L Conway |
SELL
Open market or private sale
|
Direct |
15,219
-100.0%
|
$243,504
$16.74 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 1.28M shares |
---|
Open market or private sale | 1.41M shares |
---|